Login/Sign Up

MRP ₹22982.5
(Inclusive of all Taxes)
₹3447.4 Cashback (15%)
Kintsugi 440 Injection 1's is used to treat Breast Cancer and Stomach Cancer. Kintsugi 440 Injection 1's contains Trastuzumab, which works by attaching itself to the HER2 proteins so that the cancer cells are no longer stimulated to grow. It also helps the body's immune system to destroy breast cancer cells. It should not be taken during pregnancy as it might cause fetal harm. Inform your doctor immediately if you are conceiving while on therapy. Advise women not to breastfeed while taking Kintsugi 440 Injection 1's.
Provide Delivery Location
About Kintsugi 440 Injection 1's
Kintsugi 440 Injection 1's is an anti-cancer medicine used in the treatment of HER2-positive Breast cancer and HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma. Cancer is a disease where the cells grow abnormally and divide uncontrollably. It can also be used when the cancer has spread to other parts of the body.
Kintsugi 440 Injection 1's contains Trastuzumab as an active ingredient, which belongs to the class of monoclonal antibodies. It works by inhibiting the abnormal growth of cancer cells and, finally, causes the initiation of programmed cell death.
Kintsugi 440 Injection 1's may cause certain side effects such as abdominal pain, chills, diarrhoea, fatigue, nausea, back pain, bone pain, edema, insomnia, fever, dizziness, headache, vomiting, cough, rash, and injection site reactions. If the side effects persist or bother you, please consult your doctor. Kintsugi 440 Injection 1's will be administered by a trained doctor. Hence, do not self-administer.
Avoid taking it and inform your doctor if you are allergic to Kintsugi 440 Injection 1's or its components. Inform your doctor if you have any cardiovascular conditions, lung problems, or liver/kidney disease, as it can cause adverse effects. Kintsugi 440 Injection 1's is known to cause embryo-fetal toxicity. Hence, if you are pregnant or breastfeeding, inform your doctor beforehand.
Uses of Kintsugi 440 Injection 1's
Kintsugi 440 Injection 1's is used in the treatment of Breast Cancer and Stomach Cancer. The detailed uses of Kintsugi 440 Injection 1's are as follows:

Have a query?
Directions for Use
Medicinal Benefits
Kintsugi 440 Injection 1's contains Trastuzumab, which is used for treating patients with HER2-positive breast cancer and HER2-positive metastatic gastroesophageal adenocarcinoma. This medicine works by inhibiting the excess production of a human epidermal growth factor receptor 2 (HER2) protein in the mammalian cells. This causes inhibition of the cancer cell growth and, finally, initiation of programmed cell death.
How Kintsugi 440 Injection 1's Works
Storage
What if I have taken an overdose of Kintsugi 440 Injection 1's
Drug Warnings
Kintsugi 440 Injection 1's should be avoided if you are allergic to it or any other components of this medicine. Inform your doctor if you have any lung problems, cardiovascular conditions or liver/kidney disease, as it can cause adverse effects. Kintsugi 440 Injection 1's may cause left ventricular ejection fraction, cardiomyopathy, pulmonary toxicity, exacerbations of chemotherapy-induced neutropenia, and hypersensitivity reactions during the treatment. Hence, careful observation should be performed for any reactions in the patient. Kintsugi 440 Injection 1's may cause embryo-fetal toxicity. Hence, if you are pregnant or planning to become pregnant, inform your doctor beforehand. Breastfeeding should be discontinued in nursing mothers during the treatment. Kintsugi 440 Injection 1's is not recommended for use in children as the safety and efficacy are not established.
Drug-Drug Interactions
Login/Sign Up
Drug-Food Interactions
Login/Sign Up
Diet & Lifestyle Advise
Habit Forming
Therapeutic Class
RXLupin Ltd
₹18885.5
(₹897.06/ 1ml)
RXCelon Laboratories Pvt Ltd
₹30000
(₹1230.0/ 1ml)
RXAlkem Laboratories Ltd
₹51246
(₹2101.09/ 1ml)
Alcohol
Unsafe
Avoid consumption of alcohol as it may cause serious side effects.
Pregnancy
Unsafe
Kintsugi 440 Injection 1's is not recommended for use in pregnancy as it may harm your foetus. Hence, if you are pregnant or planning pregnancy, inform your doctor before receiving Kintsugi 440 Injection 1's. Use reliable methods of birth control while on treatment with Kintsugi 440 Injection 1's.
Breast Feeding
Unsafe
Avoid nursing your child while on treatment with Kintsugi 440 Injection 1's as it can cause serious side effects to the baby.
Driving
Not applicable
-
Liver
Caution
If you have a pre-existing or a history of liver disease, inform your doctor before receiving Kintsugi 440 Injection 1's. Your doctor may adjust the dose of this medicine or prescribe a suitable alternative based on your condition.
Kidney
Caution
Limited data are available on the effect of Kintsugi 440 Injection 1's in kidney-impaired patients. Hence, if you have a pre-existing or a history of kidney disease, inform your doctor.
Children
Unsafe
Kintsugi 440 Injection 1's is not recommended for use in children as the safety and efficacy are not established.
Heart
Kintsugi 440 Injection 1's may increase the risk of heart problems. Therefore, please inform your doctor if you have any heart-related problems before using Kintsugi 440 Injection 1's.
Geriatrics
Consult your doctor
Please consult a doctor before administering Kintsugi 440 Injection 1's to geriatric patients. Your doctor will prescribe Kintsugi 440 Injection 1's if the benefits outweigh the risks.
Kintsugi 440 Injection 1's is used to treat Breast Cancer and Stomach Cancer.
Kintsugi 440 Injection 1's contains Trastuzumab, which works by inhibiting the excess production of a protein called human epidermal growth factor receptor 2 (HER2) in mammalian cells. This causes inhibition of the cancer cell growth.
Inform your doctor whether you have received any other cancer treatment. Kintsugi 440 Injection 1's may cause a decrease in left ventricular ejection fraction, cardiomyopathy, hypersensitivity reactions, pulmonary toxicity, and embryo-fetal toxicity during the treatment. Hence, inform your oncologist if you have any cardiovascular conditions, liver/kidney disease, lung problems, are pregnant, are planning to become pregnant, or are breastfeeding before receiving Kintsugi 440 Injection 1's.
Consult the doctor immediately, if you experience symptoms of an infection, such as a high temperature, chills, or feeling unwell despite a normal temperature. It could be due to a reduced white blood cell count caused by Kintsugi 440 Injection 1's, increasing your risk of severe infections. Additionally, swollen feet or ankles, stomach pain, or lower back pain may indicate heart problems.
It is recommended to wait at least 6 months after completing Kintsugi 440 Injection 1's therapy before trying to get pregnant. This is because the medication can remain in the body for some time and may potentially affect pregnancy. However, it is essential to consult the doctor for personalized advice and to ensure that it is safe for you to become pregnant after this treatment.
The duration of treatment with Kintsugi 440 Injection 1's will depend on an individual treatment plan, which your doctor will determine based on your specific condition. It may vary based on personal medical conditions and how you respond to the therapy. In some cases, the treatment duration may be shorter or longer. Always attend follow-up appointments as instructed by the doctor for effective treatment.
Fasting is not typically required before administering Kintsugi 440 Injection 1's. However, it is always best to follow the doctor's specific instructions regarding preparations before treatment. If fasting is necessary, your doctor will provide detailed guidance.
Kintsugi 440 Injection 1's should be administered through subcutaneous (SC) or intravenous (IV) routes by the doctor or nurse. Do not self-administer.
Kintsugi 440 Injection 1's should not be administered to patients with HER2-negative cancer cells as it is a monoclonal antibody that specifically targets a protein called human epidermal growth factor receptor 2 (HER2), which is present in high amounts on the surface of specific cancer cells.
The doctor may recommend heart investigations while you are taking Kintsugi 440 Injection 1's as it may potentially affect heart function. It has been associated with heart-related side effects, including a decrease in left ventricular ejection fraction, which could lead to heart failure in some patients. Monitoring heart health helps detect any issues early, ensuring prompt action to manage the risk. Always follow the doctor's recommendations for regular check-ups during treatment.
During treatment with Kintsugi 440 Injection 1's for advanced-stage disease, cardiac monitoring was conducted every 3 to 8 months for up to 2 years. However, the doctor will adjust the frequency of heart investigations based on your specific condition and response to treatment. It's essential to follow their advice for optimal monitoring and early detection of any heart-related issues.
The side effects of Kintsugi 440 Injection 1's include abdominal pain, chills, headache, diarrhoea, fatigue, nausea, back pain, bone pain, oedema, insomnia, fever, dizziness, vomiting, cough, rash, and injection site reactions. Consult the doctor if any of these side effects persist or worsen.
Country of origin
Manufacturer/Marketer address
We provide you with authentic, trustworthy and relevant information
Buy best Neoplastic Disorders products by
Intas Pharmaceuticals Ltd
Dr Reddy's Laboratories Ltd
Celon Laboratories Pvt Ltd
Natco Pharma Ltd
Cipla Ltd
Adley Formulations
BDR Pharmaceuticals Internationals Pvt Ltd
Sun Pharmaceutical Industries Ltd
Admac Lifesciences(Oncology)
Halsted Pharma Pvt Ltd
Glenmark Pharmaceuticals Ltd
Neon Laboratories Ltd
United Biotech Pvt Ltd
Alkem Laboratories Ltd
Samarth Life Sciences Pvt Ltd
Zydus Cadila
Zydus Healthcare Ltd
Emcure Pharmaceuticals Ltd
Axiommax Oncology Pvt Ltd
GLS Pharma Ltd
Mylan Pharmaceuticals Pvt Ltd
Hetero Drugs Ltd
Hetero Healthcare Pvt Ltd
Fresenius Kabi India Pvt Ltd
Pfizer Ltd
Torrent Pharmaceuticals Ltd
Cadila Healthcare Ltd
Getwell Life Sciences India Pvt Ltd
Therdose Pharma Pvt Ltd
Khandelwal Laboratories Pvt Ltd
Novartis India Ltd
Lupin Ltd
Adley Pharmaceuticals Ltd
Aureate Healthcare
Biochem Pharmaceutical Industries Ltd
RPG Life Sciences Ltd
Abbott India Ltd
Delarc Pharmaceuticals Pvt Ltd
Zee Laboratories Ltd
Amps Biotech Biotech Pvt Ltd
Shilpa Medicare Ltd
Wembrace Biopharma Pvt Ltd
Aimcad Biotech Pvt Ltd
Getwell Oncology Pvt Ltd
Msn Laboratories Pvt Ltd
Reliance Formulation Pvt Ltd
Allieva Pharma Pvt Ltd
Astra Zeneca Pharma India Ltd
Lucien Life Sciences
Getwell Pharmaceutical Pvt Ltd
MEDICAMEN BIOTECH LTD
Medion Biotech Pvt Ltd
Bhardwaj India Pvt Ltd
Caitlin Oncology
Del Trade International Pvt Ltd
Medaegis Biotek Pvt Ltd
Panacea Biotec Ltd
Cadila Pharmaceuticals Ltd
Dabur India Ltd
Oncostar Pharma Pvt Ltd
Sarabhai Chemicals (India) Pvt Ltd
Bangalore Pharmaceutical and Research Laboratory Pvt Ltd (BPRL)
Cytogen
Symbion Lifescience
Vhb Life Sciences Inc
Zuvius Lifesciences Pvt Ltd
Amneal Healthcare Pvt Ltd
Ipca Laboratories Ltd
Miracalus Pharma Pvt Ltd
Bruck Pharma Pvt Ltd
Eli Lilly and Company (India) Pvt Ltd
Hilfen Pharmaceuticals Pvt Ltd
Medicamen Biotech Ltd
Adley Oncology
Admac Pharma Ltd
Eris Life Sciences Ltd
Johnson & Johnson Pvt Ltd
Maximal Healthcare Pvt Ltd
Reliance Life Sciences Pvt Ltd
Sayre Therapeutics Pvt Ltd
Akumentis Healthcare Ltd
Biocon Ltd
Caitlin Biotech Pvt Ltd
Ferring Pharmaceuticals Pvt Ltd
Fresenius Kabi Oncology Ltd
Zuventus Healthcare Ltd
Astellas Pharma India Pvt Ltd
Boehringer Ingelheim India Pvt Ltd
Mankind Pharma Pvt Ltd
Roche Diagnostics India Pvt Ltd
Selway Lifesciences Pvt Ltd
Trikem Remedies Llp
Adley & Bdl
Aprazer Healthcare Pvt Ltd
Aureate Pharma
Caitlin Life Care
Corona Remedies Pvt Ltd
Eisai Pharmaceuticals India Pvt Ltd
GlaxoSmithKline Pharmaceuticals Ltd
Gynofem Healthcare Pvt Ltd